New PET scan could sharpen detection of neuroendocrine tumors
NCT ID NCT07102056
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study will test a new type of PET scan using a radioactive tracer called 18F-Octreotide in 152 people with or suspected of having neuroendocrine tumors. The goal is to see if this scan can more accurately locate tumors, guide treatment decisions, and help predict how the disease will progress. Researchers will also explore its use in measuring tumor size, grading, and identifying genetic types.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
18F-Octreotide (a radioactive tracer for PET imaging)
What this could lead to
If successful, this imaging method could help doctors more accurately locate neuroendocrine tumors, choose the best treatment, and predict patient outcomes.
What could go wrong
This is an early-stage study with only 152 participants, so results may not apply to everyone. The new scan may not be significantly better than current methods.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROENDOCRINE TUMORS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••